Press coverage about AtriCure (NASDAQ:ATRC) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 46.4890680402312 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- SeaSpine (SPNE) & AtriCure (ATRC) Head to Head Review (americanbankingnews.com)
- Meridian Bioscience (VIVO) versus AtriCure (ATRC) Head-To-Head Review (americanbankingnews.com)
- Active-Investors: Free Research Report as ConforMIS Reported Better Than Expected Results (finanznachrichten.de)
- AtriCure Inc. (ATRC) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
Shares of AtriCure (NASDAQ ATRC) traded up $0.08 during trading hours on Tuesday, hitting $20.20. The company’s stock had a trading volume of 23,420 shares, compared to its average volume of 222,974. AtriCure has a 12 month low of $14.88 and a 12 month high of $25.18. The firm has a market capitalization of $679.11, a PE ratio of -24.24 and a beta of 0.30. The company has a quick ratio of 1.87, a current ratio of 2.58 and a debt-to-equity ratio of 0.23.
A number of analysts recently issued reports on the company. ValuEngine raised AtriCure from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. TheStreet cut AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. Canaccord Genuity lifted their price objective on AtriCure from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of AtriCure in a research report on Tuesday, February 27th. Finally, BidaskClub raised AtriCure from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.67.
In other AtriCure news, SVP Justin J. Noznesky sold 4,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $17.03, for a total value of $68,120.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 11.90% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.themarketsdaily.com/2018/03/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-atricure-atrc-share-price.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.